

**Revised 3 Sept. 2010 rm (Vers. 3.1)****RUO in the USA**

*Please use only the valid version of the package insert provided with the kit.*

### **Name and Intended Use**

Anti-Prothrombin Screen is an indirect solid phase enzyme immunoassay (ELISA) for measurement of IgG, IgM and IgA class class autoantibodies against prothrombin in human serum or plasma.

### **PRINCIPLE OF THE TEST**

Highly purified prothrombin is bound to microwells. Antibodies against this antigen, if present in diluted serum or plasma, bind to the antigen. Washing of the microwells removes unspecific bound serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human IgG, IgM and IgA immunologically detect the bound donor antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue colour. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow colour is measured photometrically at 450 nm. The amount of colour is directly proportional to the concentration of IgG, IgM and IgA antibodies present in the original sample.

### **WARNINGS AND PRECAUTIONS**

1. All reagents of this kit are strictly intended for research use only.
2. Do not interchange kit components from different lots.
3. Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
4. Avoid contact with the TMB (3,3',5,5'-Tetramethyl-benzidine). If TMB comes into contact with skin, wash thoroughly with water and soap.
5. Avoid contact with the Stop Solution which is acid. If it comes into contact with skin, wash thoroughly with water and seek medical attention.
6. Some kit components (i.e. Controls, Sample buffer and Buffered Wash Solution) contain Sodium Azide as preservative. Sodium Azide ( $\text{NaN}_3$ ) is highly toxic and reactive in pure form. At the product concentrations (0.09%), though not hazardous. Despite the classification as non-hazardous, we strongly recommend using prudent laboratory practices (see 8., 9., 10.)
7. Some kit components contain Proclin 300 as preservative. When disposing reagents containing Proclin 300, flush drains with copious amounts of water to dilute the components below active levels.
8. Wear disposable gloves while handling specimens or kit reagents and wash hands thoroughly afterwards.
9. Do not pipette by mouth.
10. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled.
11. Avoid contact between the buffered Peroxide Solution and easily oxidized materials; extreme temperature may initiate spontaneous combustion.

## DRG® Anti-Prothrombin Screen ELISA (EIA-3614)



Revised 3 Sept. 2010 rm (Vers. 3.1)

**RUO** in the USA

### CONTENTS OF THE KIT

Package size	96 determ.
Qty.1	Divisible <b>microplate</b> consisting of 12 modules of 8 wells each, coated with mixture of highly purified prothrombin. Ready to use.
6 vials, 1.5 ml each	Combined <b>calibrators</b> with Anti-Prothrombin antibodies (A-F) in a serum/buffer matrix (PBS, BSA, NaN <sub>3</sub> <0.1% (w/w)) containing: 0; 6.3; 12.5; 25; 50; and 100 U/ml. Ready to use.
2 vials, 1.5 ml each	Anti-Prothrombin <b>controls</b> in a serum/buffer matrix (PBS, BSA, NaN <sub>3</sub> <0.1% (w/w)) positive (1) and negative (2), for the respective concentrations see the enclosed Quality Control Certificate. Ready to use.
1 vial, 20 ml	<b>Sample buffer</b> (Tris, NaN <sub>3</sub> <0.1% (w/w)), yellow, concentrate (5x).
1 vial, 15 ml	<b>Enzyme conjugate</b> solution (PBS, Proclin 300 <0.5% (v/v)), (light red) containing polyclonal rabbit anti-human IgG, polyclonal rabbit anti-human IgM and polyclonal rabbit anti-human IgA; labelled with horseradish peroxidase. Ready to use.
1 vial, 15 ml	<b>TMB substrate solution</b> . Ready to use.
1 vial, 15 ml	<b>Stop solution</b> (contains acid). Ready to use.
1 vial, 20 ml	<b>Wash solution</b> (PBS, NaN <sub>3</sub> <0.1% (w/w)), concentrate (50x).

### STORAGE AND STABILITY

1. Store the kit at 2-8 °C.
2. Keep microplate wells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage and usage.
5. Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8 °C.

### MATERIALS REQUIRED

#### Equipment

- Microplate reader capable of endpoint measurements at 450 nm
- Multi-Channel Dispenser or repeatable pipette for 100 µl
- Vortex mixer -Pipettes for 10 µl, 100 µl and 1000 µl
- Laboratory timing device

## DRG® Anti-Prothrombin Screen ELISA (EIA-3614)



Revised 3 Sept. 2010 rm (Vers. 3.1)

**RUO** in the USA

- Data reduction software

### Preparation of reagents

- Distilled or deionised water
- Graduated cylinder for 100 and 1000 ml
- Plastic container for storage of the wash solution

### SPECIMEN COLLECTION, STORAGE AND HANDLING

1. Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
2. Allow blood to clot and separate the serum by centrifugation.
3. Test serum should be clear and non-hemolysed. Contamination by hemolysis or lipemia is best avoided, but does not interfere with this assay.
4. Specimens may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.
5. Avoid repetitive freezing and thawing of serum samples. This may result in variable loss of autoantibody activity.
6. Testing of heat-inactivated sera is not recommended.

### PROCEDURAL NOTES

1. Do not use kit components beyond their expiration dates.
2. Do not interchange kit components from different lots.
3. All materials must be at room temperature (20-28 °C).
4. Have all reagents and samples ready before start of the assay. Once started, the test must be performed without interruption to get the most reliable and consistent results.
5. Perform the assay steps only in the order indicated.
6. Always use fresh sample dilutions.
7. Pipette all reagents and samples into the bottom of the wells.
8. To avoid carryover contamination, change the tip between samples and different kit controls.
9. It is important to wash microwells thoroughly and remove the last droplets of wash buffer to achieve best results.
10. All incubation steps must be accurately timed.
11. Control sera or pools should routinely be assayed as unknowns to check performance of the reagents and the assay.
12. Do not re-use microplate wells.

For all controls, the respective concentrations are provided on the labels of each vial. Using these concentrations a calibration curve may be calculated to read off the donor results semi-quantitatively.

Revised 3 Sept. 2010 rm (Vers. 3.1)

RUO in the USA

**PREPARATION OF REAGENTS****Preparation of sample buffer**

Dilute the contents of each vial of the sample buffer concentrate (5x) with distilled or deionised water to a final volume of 100 ml prior to use.

Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

**Preparation of wash solution**

Dilute the contents of each vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

**Sample preparation**

Dilute all samples **1:100** with sample buffer before assay.

Therefore combine 10 µl of sample with 990 µl of sample buffer in a polystyrene tube. Mix well.

Controls are ready to use and need not be diluted.

**TEST PROCEDURE**

1. Prepare a sufficient number of microplate modules to accommodate controls and prediluted donor samples.
2. Pipette **100 µl** of calibrators, controls and prediluted donor samples in duplicate into the wells.

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>
<i>A</i>	SA	SE	P1	P5		
<i>B</i>	SA	SE	P1	P5		
<i>C</i>	SB	SF	P2	P..		
<i>D</i>	SB	SF	P2	P..		
<i>E</i>	SC	C1	P3			
<i>F</i>	SC	C1	P3			
<i>G</i>	SD	C2	P4			
<i>H</i>	SD	C2	P4			

SA - SF: standards A to F

P1, P2... donor sample 1, 2 ...

C1: positive control

C2: negative control

3. Incubate for 30 minutes at room temperature (20-28 °C)
4. Discard the contents of the microwells and wash 3 times with **300 µl** of wash solution.
5. Dispense **100 µl** of enzyme conjugate into each well.
6. Incubate for 15 minutes at room temperature.
7. Discard the contents of the microwells and wash 3 times with **300 µl** of wash solution.
8. Dispense **100 µl** of TMB substrate solution into each well.

## DRG® Anti-Prothrombin Screen ELISA (EIA-3614)



Revised 3 Sept. 2010 rm (Vers. 3.1)

**RUO** in the USA

9. Incubate for 15 minutes at room temperature.
10. Add **100 µl** of stop solution to each well of the modules and incubate for 5 minutes at room temperature.
11. Read the optical density at 450 nm and calculate the results. Bi-chromatic measurement with a reference at 600-690 nm is recommended.

The developed colour is stable for at least 30 minutes. Read optical densities during this time.

### Automation

The Anti-Prothrombin Screen ELISA is suitable for use on open automated ELISA processors. The test procedure detailed above is appropriate for use with or without automation.

### INTERFERING SUBSTANCES

No interference has been observed with haemolytic (up to 1000 mg/dL), lipemic (up to 3 g/dL triglycerides) or bilirubin (up to 40 mg/dL) containing sera. Nor have any interfering effects been observed with the use of anticoagulants. However for practical reasons it is recommended that grossly hemolysed or lipemic samples should be avoided.

### REFERENCES / Literature

1. Vaarala O., Puurunen M., Manttari M., et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. *Thromb. Haemost.*, Mar 1996, 75 (3) p456-9
2. Puurunen M., Vaarala O., Julkunen H., et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in donors with systemic lupus erythematosus. *Clin. Immunol. Immunopathol.*, Jul 1996, 80 (1) p16-22
3. Palosuo T., Virtamo J., Haukka J., et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men--a nested case control study. *Thromb. Haemost.*, Oct. 1997, 78 (4) p1178-82
4. Bertolaccini M. L., Atsumi T., Khamashta M.A., et al. Autoantibodies to human prothrombin and clinical manifestations in 207 donors with systemic lupus erythematosus. *J. Rheumatol.* Jun 1998, 25 (6) p1104-8
5. Sorice M., Pittoni V., Circella A., et al. Anti-prothrombin but not "pure" anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome [letter]. *Thromb. Haemost.* Oct 1998, 80 (4) p713-5
6. Glli M., Beretta G., Daldossi M., et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in donors with antiphospholipid antibodies. *Thromb. Haemost.*, Mar 1997, 77 (3) p486-91
7. Sherer Y. et al Anti-Prothrombin antibodies in thrombosis and atherosclerosis. *Atherosclerosis and Autoimmunity* 2001; 185-190
8. Miyakis S., Lockshin M. D., Atsumi T., Branch D. W., Brey R. L., Cervera R., Derksen R. H. W. M., de Groot P. G., Koike T., Meroni P. L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P. G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb. Haemost.* 2006; 4: 295–306.